Kailera Therapeutics, Inc. KLRA
12.20 USD -0.37 (-2.94%)
Regular-session close
12.25 +0.05 +0.41%
After hours · Nov 17, 7:18 PM ET
11.86 Day range 12.68
10.00 52-week range 26.00
- YTD
- -53.08%
- 1 year
- -53.08%
News
globenewswire.com Kailera Therapeutics to Present at ObesityWeek 2026 Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum Real-world obesity management presentation highlights the…benzinga.com Canaccord Genuity Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $44 Canaccord Genuity analyst Edward Nash initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $44.
benzinga.com Kailera Therapeutics Q3 EPS $(0.74) Beats $(1.02) Estimate Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(1.02) by 27.45 percent.
globenewswire.com Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program…
globenewswire.com Kailera Therapeutics to Participate in November Investor Conferences Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences
defenseworld.net Kailera Therapeutics (NASDAQ:KLRA) Shares Climb 7.6% – Here’s What Happened Kailera Therapeutics, Inc. (NASDAQ: KLRA - Get Free Report)'s stock price was up 7.6% on Friday. The stock traded as high as $10.76 and last traded at $10.76. 293,082 shares were traded during…
defenseworld.net Kailera Therapeutics (NASDAQ:KLRA) Sets New 12-Month Low – Time to Sell? Kailera Therapeutics, Inc. (NASDAQ: KLRA - Get Free Report)'s share price reached a new 52-week low on Monday. The stock traded as low as $10.20 and last traded at $10.20, with a volume of 51759…
globenewswire.com Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting - New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline…
fool.com Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy Could this be what Novo needs to turn things around?
globenewswire.com Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection - Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher - Topline data now expected in mid-2028 WALTHAM,…
seekingalpha.com Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive…
globenewswire.com Kailera Therapeutics to Participate in September Investor Conferences WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today…
defenseworld.net Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA Atlas Venture Life Science Advisors LLC acquired a new position in shares of Kailera Therapeutics, Inc. (NASDAQ: KLRA) in the second quarter, according to its most recent 13F filing with the…
247wallst.com Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore Kailera Therapeutics (NASDAQ:KLRA) closed most recently at $18.51, between a post-IPO high of $28.23 and low of $16.39, with a $2.40 billion market cap.
fool.com 2 GLP-1 Stocks That Could Double Your Money by 2031 They are fairly risky, but their potential upside is massive.
globenewswire.com Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled,…
fool.com 2 Beaten-Down GLP-1 Stocks to Buy on the Dip Don't wait until clinical milestones send their share prices soaring.
seekingalpha.com Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win Kailera is building a multi-modal obesity franchise with exclusive global rights to Hengrui Pharma's obesity portfolio, leveraging late-stage assets and ongoing data. KLRA's robust cash position—over…
benzinga.com Why Is Kailera Therapeutics Stock Falling Tuesday? Kailera Therapeutics Inc. (NASDAQ:KLRA) stock fell about 9% on Tuesday after the company reported positive topline results from two Phase 3 trials of its oral GLP-1 drug candidate HRS-7535/KAI-7535…
reuters.com Kailera's GLP-1 drug meets main goal of late-stage trials Kailera Therapeutics said on Tuesday its GLP-1 drug for patients with diabetes and obesity met the main goal of two-late stage trials.
globenewswire.com Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Ka
etftrends.com Biotech ETF Index Surges 10% After Rebalance After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's…
